- Home
- LVTX vs ADVB Comparison
LVTX vs ADVB Comparison
Compare LVTX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- ADVB
- Stock Information
- Founded
- LVTX 2016
- ADVB 2014
- Country
- LVTX Netherlands
- ADVB United States
- Employees
- LVTX N/A
- ADVB N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- LVTX Health Care
- ADVB Health Care
- Exchange
- LVTX Nasdaq
- ADVB Nasdaq
- Market Cap
- LVTX 33.1M
- ADVB 36.1M
- IPO Year
- LVTX 2021
- ADVB 2025
- Fundamental
- Price
- LVTX $1.29
- ADVB $0.95
- Analyst Decision
- LVTX Hold
- ADVB
- Analyst Count
- LVTX 3
- ADVB 0
- Target Price
- LVTX $1.75
- ADVB N/A
- AVG Volume (30 Days)
- LVTX 50.0K
- ADVB 196.1K
- Earning Date
- LVTX 05-14-2025
- ADVB 01-01-0001
- Dividend Yield
- LVTX N/A
- ADVB N/A
- EPS Growth
- LVTX N/A
- ADVB N/A
- EPS
- LVTX N/A
- ADVB N/A
- Revenue
- LVTX $4,990,000.00
- ADVB N/A
- Revenue This Year
- LVTX N/A
- ADVB N/A
- Revenue Next Year
- LVTX N/A
- ADVB N/A
- P/E Ratio
- LVTX N/A
- ADVB N/A
- Revenue Growth
- LVTX N/A
- ADVB N/A
- 52 Week Low
- LVTX $0.85
- ADVB $0.86
- 52 Week High
- LVTX $2.53
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- LVTX 51.81
- ADVB N/A
- Support Level
- LVTX $1.18
- ADVB N/A
- Resistance Level
- LVTX $1.34
- ADVB N/A
- Average True Range (ATR)
- LVTX 0.08
- ADVB 0.00
- MACD
- LVTX 0.00
- ADVB 0.00
- Stochastic Oscillator
- LVTX 68.75
- ADVB 0.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.